Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 3M2, Canada.
College of Pharmacy, Yeungnam University, Gyeongsan, 38541, Republic of Korea.
Arch Pharm Res. 2017 Dec;40(12):1345-1355. doi: 10.1007/s12272-017-0986-y. Epub 2017 Nov 27.
The intestinal mucosa and liver have long been considered as the main sites of drug metabolism, and the contribution of gut microbiota to drug metabolism has been under-estimated. However, it is now generally accepted that the gut microbiota plays an important role in drug metabolism prior to drug absorption or during enterohepatic circulation via various microbial enzymatic reactions in the intestine. Moreover, some drugs are metabolized by gut microbiota to specific metabolite(s) that cannot be formed in the liver. More importantly, the metabolism of drugs by gut microbiota prior to absorption can alter the systemic bioavailability of certain drugs. Therefore, understanding drug metabolism by gut microbiota is critical for explaining changes in the pharmacokinetics of drugs, which may cause significant alterations in drug-induced pharmacodynamics and toxicities. In this review, we describe recent progress with regard to the role of metabolism by gut microbiota in some drug-induced alterations of either pharmacological or toxicological effects to emphasize the clinical importance of gut microbiota for safe and effective use of drugs.
肠道黏膜和肝脏长期以来一直被认为是药物代谢的主要部位,而肠道微生物群对药物代谢的贡献一直被低估。然而,现在人们普遍认为,肠道微生物群在药物吸收之前或在药物吸收过程中通过肠内各种微生物酶反应在药物代谢中起着重要作用。此外,一些药物被肠道微生物群代谢为特定的代谢物(s),这些代谢物不能在肝脏中形成。更重要的是,肠道微生物群在吸收前对药物的代谢可以改变某些药物的全身生物利用度。因此,了解肠道微生物群对药物的代谢对于解释药物的药代动力学变化至关重要,这可能导致药物诱导的药效学和毒性的显著改变。在这篇综述中,我们描述了肠道微生物群代谢在某些药物诱导的药理或毒理作用改变中的作用的最新进展,强调了肠道微生物群对药物安全有效使用的临床重要性。